Definium Therapeutics says Phase 3 Panorama trial meets primary endpoint for DT120 ODT in generalized anxiety disorder

• Definium Therapeutics reported positive topline Phase 3 Panorama results for DT120 ODT in generalized anxiety disorder; results were released now.
• Trial met the main goal and all key secondary goals, showing clinically meaningful improvement versus placebo with rapid, sustained benefit.
• DT120 ODT was generally well tolerated, with no new safety concerns flagged in the study.
• Pre-NDA meeting is scheduled for 4Q 2026; NDA filing is anticipated in 1H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609140700BIZWIRE_USPR_____20260914_BW329364) on September 14, 2026, and is solely responsible for the information contained therein.